CapsoVision, Inc. (CV)
| Market Cap | 330.26M |
| Revenue (ttm) | 13.56M +12.6% |
| Net Income | -26.97M |
| EPS | -0.75 |
| Shares Out | 49.96M |
| PE Ratio | n/a |
| Forward PE | n/a |
| Dividend | n/a |
| Ex-Dividend Date | n/a |
| Volume | 185,809 |
| Open | 6.55 |
| Previous Close | 6.50 |
| Day's Range | 6.41 - 6.73 |
| 52-Week Range | 3.43 - 15.37 |
| Beta | n/a |
| Analysts | Strong Buy |
| Price Target | 10.00 (+51.29%) |
| Earnings Date | May 14, 2026 |
About CV
CapsoVision, Inc., a medical technology company, manufactures and markets endoscopic video imaging devices focused on internal imaging of the gastrointestinal system. The company offers CapsoCam Plus, a capsule endoscopy system for visualization of the small bowel mucosa in adults and children aged 2 years and above; and CapsoCam Colon for visualization of the colon and detection and measurement of polyps, as well as develops CapsoColon 3D for large intestines (colon). It also provides CapsoCloud cloud-based software-as-a-service ecosystem as a... [Read more]
Financial Performance
In 2025, CapsoVision's revenue was $13.55 million, an increase of 15.29% compared to the previous year's $11.76 million. Losses were -$25.32 million, 27.2% more than in 2024.
Financial StatementsAnalyst Summary
According to one analyst, the rating for CV stock is "Strong Buy" and the 12-month stock price target is $10.0.
News
CapsoVision Transcript: AGM 2026
The meeting covered director elections, auditor ratification, and reaffirmed governance commitments. All proposals passed, with final results to be filed in a Form 8-K. No shareholder questions were raised.
CapsoVision Earnings Call Transcript: Q1 2026
Revenue remained stable at $2.8M in Q1 2026, with strong utilization and expanding clinical adoption. AI-assisted capabilities are on track for mid-year launch, and a $14M private placement bolstered the balance sheet.
CapsoVision Earnings release: Q1 2026
CapsoVision released its Q1 2026 earnings on May 14, 2026, summarizing the period's financial results.
CapsoVision Quarterly report: Q1 2026
CapsoVision has published its Q1 2026 quarterly earnings report on May 14, 2026.
CapsoVision Reports First Quarter 2026 Financial Results
SARATOGA, Calif., May 14, 2026 (GLOBE NEWSWIRE) -- CapsoVision, Inc. (NASDAQ: CV), a commercial-stage medical technology company developing advanced imaging and AI-enabled capsule endoscopy solutions,...
CapsoVision to Release First Quarter 2026 Financial Results on May 14, 2026
SARATOGA, Calif., April 30, 2026 (GLOBE NEWSWIRE) -- CapsoVision, Inc. (NASDAQ: CV), a commercial-stage medical technology company developing advanced imaging and AI-enabled capsule endoscopy solution...
CapsoVision Proxy statement: Proxy filing
CapsoVision filed a proxy statement on April 28, 2026, providing details for shareholder voting and corporate governance matters.
CapsoVision files to sell 2.87M shares of common stock for holders
16:39 EDT CapsoVision (CV) files to sell 2.87M shares of common stock for holders
CapsoVision Registration statement: Registration filing
CapsoVision filed a registration statement on April 17, 2026, providing details about a securities offering with the SEC.
CapsoVision price target lowered to $10 from $14 at Benchmark
Benchmark analyst Bruce Jackson lowered the firm’s price target on CapsoVision (CV) to $10 from $14 and keeps a Speculative Buy rating on the shares after the company reported Q4…
CapsoVision Earnings Call Transcript: Q4 2025
Revenue grew 15% year-over-year in 2025, driven by CapsoCam Plus adoption and new account growth. AI-enabled product pipeline advanced, with pivotal studies and regulatory submissions on track. Balance sheet strengthened by $14 million equity raise.
CapsoVision Annual report: Q4 2025
CapsoVision has published its Q4 2025 annual report on March 26, 2026.
CapsoVision Earnings release: Q4 2025
CapsoVision released its Q4 2025 earnings on March 26, 2026, summarizing the period's financial results.
CapsoVision Slides: Corporate presentation
CapsoVision has posted slides in relation to its latest quarterly earnings report, which was published on March 26, 2026.
CapsoVision price target raised to $11 from $7 at Roth Capital
Roth Capital raised the firm’s price target on CapsoVision (CV) to $11 from $7 and keeps a Buy rating on the shares after its Q4 pre-announcement and the closing of…
CapsoVision Transcript: The 38th Annual Roth Conference
CapsoVision highlighted its AI-powered capsule endoscopy platform, targeting major GI markets with a robust pipeline for colon, pancreas, esophagus, and stomach imaging. Strategic partnerships and recent financing support expansion and R&D through 2026.
CapsoVision jumps over 20% after announcing preliminary Q4 revenue
CapsoVision (CV) on Friday announced the closing of a $14M private placement in public equity financing pursuant to a securities purchase agreement entered into by the company with selected accredited...
CapsoVision price target raised to $11 from $7 at Roth Capital
Roth Capital raised the firm’s price target on CapsoVision (CV) to $11 from $7 and keeps a Buy rating on the shares after the company announced preliminary sales for Q4…
CapsoVision announces $14M private placement financing
CapsoVision (CV) “announced the closing of a $14 million private placement in public equity financing pursuant to a securities purchase agreement entered into by the company with selected accredited i...
CapsoVision Announces $14 Million Private Placement Financing
Reports Preliminary, Unaudited Fourth-Quarter and Full Year 2025 Financial Results Reports Preliminary, Unaudited Fourth-Quarter and Full Year 2025 Financial Results
CapsoVision to Release Fourth Quarter and Full Year 2025 Financial Results on Thursday, March 26, 2026
SARATOGA, Calif., March 12, 2026 (GLOBE NEWSWIRE) -- CapsoVision, Inc. (NASDAQ: CV), a commercial-stage medical technology company developing advanced imaging and AI-enabled capsule endoscopy solution...
CapsoVision price target raised to $14 from $5 at Benchmark
Benchmark raised the firm’s price target on CapsoVision (CV) to $14 from $5 and keeps a Speculative Buy rating on the shares after the company announced that it submitted a…
CapsoVision submits 510(k) application to FDA for CapsoCam Plus
CapsoVision (CV) announced submission of its 510(k) application to the FDA for its proprietary AI-assisted module for CapsoCam Plus. The company intends for U.S. commercialization activities to commen...
CapsoVision Inc trading halted, volatility trading pause
15:55 EST CapsoVision (CV) Inc trading halted, volatility trading pause
CapsoVision Inc trading resumes
16:00 EST CapsoVision (CV) Inc trading resumes